Novo Nordisk’s Karsten Munk Knudsen is targeting 800 million obese people globally. Read More
As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
Related Posts
Expect volatility: Climate change, speculation and Trump brew a perfect storm for coffee prices in 2025
Coffee demand has outstripped supply for several years now, prompting a flurry of speculative buying that further drove up market…
The absurdity of Donald Trump’s trade war
Unlock the White House Watch newsletter for free Your guide to what the 2024 US election means for Washington and…
Survey: Most Americans wouldn’t take GLP-1 drugs for weight loss
GLP-1s, or glucagon-like peptide-1 agonist drugs, are seemingly everywhere. In recent years, this class of weight-loss and Type 2 diabetes…